keyword
MENU ▼
Read by QxMD icon Read
search

Colitis, ulcerative

keyword
https://read.qxmd.com/read/30779922/microrna-31-reduces-inflammatory-signaling-and-promotes-regeneration-in-colon-epithelium-and-delivery-of-mimics-in-microspheres-reduces-colitis-in-mice
#1
Yuhua Tian, Jiuzhi Xu, Yuan Li, Ran Zhao, Sujuan Du, Cong Lv, Wei Wu, Ruiqi Liu, Xiaole Sheng, Yongli Song, Xueyun Bi, Guilin Li, Mengzhen Li, Xi Wu, Pengbo Lou, Huiwen You, Wei Cui, Jinyue Sun, Jianwei Shuai, Fazheng Ren, Bing Zhang, Mingzhou Guo, Xiaohua Hou, Kaichun Wu, Lixiang Xue, Hongquan Zhang, Maksim V Plikus, Yingzi Cong, Christopher J Lengner, Zhanju Liu, Zhengquan Yu
BACKGROUND & AIMS: Levels of microRNA 31 (MIR31) are increased in intestinal tissues from patients with inflammatory bowel diseases and colitis-associated neoplasias. We investigated the effects of this microRNA on intestinal inflammation by studying mice with colitis. METHODS: We obtained colon biopsy samples from 82 patients with ulcerative colitis (UC), 79 patients with Crohn's disease (CD), and 34 healthy individuals (controls) at Shanghai Tenth People's Hospital...
February 16, 2019: Gastroenterology
https://read.qxmd.com/read/30779888/porous-polymeric-microparticles-as-an-oral-drug-platform-for-effective-ulcerative-colitis-treatment
#2
Xin Zhou, Qiubing Chen, Ya Ma, Yamei Huang, Shuangquan Gou, Bo Xiao
Porous microparticles (MPs) have been regarded as a promising vehicle for drug delivery. Herein, porous MPs and their counterparts (non-porous MPs) were produced by a conventional emulsion-solvent evaporation method in the presence and absence of ammonium bicarbonate, and curcumin (CUR) was encapsulated into these MPs during the preparation process. The obtained MPs possessed desirable diameters of around 1.2 μm and negative zeta potentials of approximately -28 mV. It was found that the release rate of CUR was remarkably increased with the introduction of pores in MPs...
February 16, 2019: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/30778832/co-existent-ulcerative-colitis-and-guillain-barr%C3%A3-syndrome-a-case-report-and-literature-review
#3
Kentaro Tominaga, Atsunori Tsuchiya, Hiroki Sato, Atsushi Kimura, Chiyumi Oda, Kazunori Hosaka, Yuzo Kawata, Naruhiro Kimura, Kazunao Hayashi, Junji Yokoyama, Shuji Terai
Ulcerative colitis (UC) is a chronic and recurrent inflammatory disease involving the intestine, and Guillain-Barré Syndrome (GBS) is rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. UC and GBS can be caused by immune system abnormalities and can co-exist. To date, there are 7 reported cases of GBS in patients with UC. However, only one patient developed UC after GBS treatment. We report a rare case of UC that appeared after intravenous immunoglobulin therapy for GBS...
February 18, 2019: Clinical Journal of Gastroenterology
https://read.qxmd.com/read/30775453/analysis-of-ph-dose-dependent-growth-of-sulfate-reducing-bacteria
#4
Ivan Kushkevych, Dani Dordević, Monika Vítězová
Lower intraluminal colonic pH is an indication for the development of inflammatory bowel disease including active ulcerative colitis. Involvement of intestinal sulfate-reducing bacteria in decreasing bowel pH by the production of H2 S and acetate as well as their sensitivity has never been reported before. The study of the relative pH and survival of Desulfovibrio piger Vib-7 by monitoring sulfate reduction parameters was the aim of this work. Monitoring was done through the measurement of bacterial growth (biomass), dissimilatory sulfate reduction parameters: sulfate consumption, lactate oxidation, hydrogen sulfide and acetate production...
2019: Open Medicine (Warsaw, Poland)
https://read.qxmd.com/read/30775357/central-venous-sinus-thrombosis-in-a-boy-with-acute-severe-ulcerative-colitis
#5
Rafael Martín-Masot, Pilar Ortiz Pérez, Juliana Serrano Nieto, María Martínez León, Antonia Pascual Martínez, Javier Blasco-Alonso, Victor Manuel Navas-López
Cerebral venous sinus thrombosis (CVST) in childhood is uncommon. Certain diseases predispose patients to CVST, such as inflammatory bowel disease (IBD), which is considered a risk factor for developing thrombosis, which in turn is considered an extraintestinal manifestation of IBD. The use of prophylaxis in certain patients is a controversial topic. We present the case of a 5-years-old child with ulcerative colitis, who presented with transverse sinus thrombosis immediately after colectomy. Considering the recent recommendations on prophylaxis in this disease, our patient and probably many others would benefit from establishing treatment with low-molecular-weight heparin...
2019: Frontiers in Pediatrics
https://read.qxmd.com/read/30774844/effect-of-irritable-bowel-syndrome-on-sleep-quality-and-quality-of-life-of-inflammatory-bowel-disease-in-clinical-remission
#6
Ali Zargar, Somayeh Ahmadi Gooraji, Bahareh Keshavarzi, Ali Akbar Haji Aghamohammadi
Background: Inflammatory bowel disease (IBD) as a chronic and debilitating disease is affected by sleep disturbance which increases the risk of malignancy. Sleep disturbance is more common in irritable bowel syndrome (IBS) and few reported studies have assessed its role in IBD. We evaluated the effect of IBS on sleep quality and quality of life (QOL) of IBD patients in clinical remission. Methods: In a cross-sectional study, 115 IBD patients in clinical remission aged from 14 to 70 years referred to gastroenterology outpatient departments and private gastroenterology offices from 2007 to 2016...
2019: International Journal of Preventive Medicine
https://read.qxmd.com/read/30774593/cellular-mechanisms-of-etrolizumab-treatment-in-inflammatory-bowel-disease
#7
Charlotte Lichnog, Sha Klabunde, Emily Becker, Franklin Fuh, Philipp Tripal, Raja Atreya, Entcho Klenske, Rich Erickson, Henry Chiu, Chae Reed, Shan Chung, Clemens Neufert, Imke Atreya, Jacqueline McBride, Markus F Neurath, Sebastian Zundler
Background: Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in several phase III trials. Mechanistically, etrolizumab is known to block β7 integrin ligand binding and reduces intestinal trafficking of β7-expressing cells. Etrolizumab blocks β7 integrin ligand binding and reduces β7-positive lymphocyte migration and retention in the inflamed gut mucosa, but the exact mechanisms by which this inhibition occurs are not fully understood...
2019: Frontiers in Pharmacology
https://read.qxmd.com/read/30774408/fecal-microbiota-profiles-in-treatment-na%C3%A3-ve-pediatric-inflammatory-bowel-disease-associations-with-disease-phenotype-treatment-and-outcome
#8
Christine Olbjørn, Milada Cvancarova Småstuen, Espen Thiis-Evensen, Britt Nakstad, Morten Harald Vatn, Jørgen Jahnsen, Petr Ricanek, Simen Vatn, Aina E F Moen, Tone M Tannæs, Jonas C Lindstrøm, Johan D Söderholm, Jonas Halfvarson, Fernando Gomollón, Christina Casén, Magdalena K Karlsson, Rahul Kalla, Alex T Adams, Jack Satsangi, Gøri Perminow
Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD subgroups, and treatment outcomes. Patients and methods: Fecal samples were collected from 235 children below 18 years of age. Eighty children had Crohn's disease (CD), 27 ulcerative colitis (UC), 3 IBD unclassified, 50 were non-IBD symptomatic patients, and 75 were healthy...
2019: Clinical and Experimental Gastroenterology
https://read.qxmd.com/read/30774277/fatigue-in-children-and-adolescents-with-inflammatory-bowel-disease
#9
Els Van de Vijver, Ann Van Gils, Laura Beckers, Yannick Van Driessche, Nicolette Dorien Moes, Patrick Ferry van Rheenen
AIM: To identify factors other than active disease and anemia that contribute to fatigue in pediatric inflammatory bowel disease (IBD). METHODS: We performed an electronic search in Medline and EMBASE from their inception to May 2017 using the search term "fatigue" or the related keywords "physical impairment" and "inflammatory bowel disease" with the filter "child" (age 0-18 years). Cross-sectional and case-control studies were included...
February 7, 2019: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/30773746/the-impact-of-allergic-rhinitis-on-gastrointestinal-disorders-among-young-adults
#10
Sai-Wai Ho, Ching-Pin Lin, Min-Sho Ku
BACKGROUND: An association between allergic rhinitis (AR) and digestive diseases (DDs) has been reported; however, studies have only focused on the prevalence of DDs in populations of patients with AR. In individuals with specific DDs, the impact of AR on the frequency of clinical visits for each DD has not been studied. Moreover, the association between topical steroid usage for AR and DDs has not been investigated. METHODS: Data from 16 526 men and 18 438 women, aged 21 to 30 years, were collected from a national database...
February 17, 2019: Journal of Evaluation in Clinical Practice
https://read.qxmd.com/read/30773667/comparative-safety-and-effectiveness-of-tumor-necrosis-factor-%C3%AE-antagonists-and-vedolizumab-in-elderly-ibd-patients-a-multicentre-study
#11
Tomer Adar, David Faleck, Saranya Sasidharan, Kelly Cushing, Nienke Z Borren, Niharika Nalagatla, Ryan Ungaro, Wayne Sy, Samuel C Owen, Anish Patel, Benjamin L Cohen, Ashwin N Ananthakrishnan
BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age. METHODS: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites...
February 17, 2019: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/30773656/sex-based-differences-in-the-incidence-of-inflammatory-bowel-diseases-pooled-analysis-of-population-based-studies-from-the-asia-pacific-region
#12
Shailja C Shah, Hamed Khalili, Chung-Yu Chen, Hyeong Sik Ahn, Siew C Ng, Johan Burisch, Jean-Frederic Colombel
BACKGROUND: There appear to be differences in risk factor profiles for IBD between Asia-Pacific and Western populations, which might suggest idiosyncrasies in pathogenesis. Recently, sex-based differences in IBD according to the age of diagnosis have been described in Western populations. AIM: Our primary aim was to identify whether sex-based differences in IBD incidence similarly exist across the age spectrum for Asia-Pacific populations. METHODS: We identified Asia-Pacific population-based cohorts where IBD incidence data stratified by sex were available for the full age spectrum...
February 17, 2019: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/30772902/untargeted-metabolomics-and-inflammatory-markers-profiling-in-children-with-crohn-s-disease-and-ulcerative-colitis-a-preliminary-study
#13
Urszula Daniluk, Jaroslaw Daniluk, Rafal Kucharski, Tomasz Kowalczyk, Karolina Pietrowska, Paulina Samczuk, Aleksandra Filimoniuk, Adam Kretowski, Dariusz Lebensztejn, Michal Ciborowski
BACKGROUND: Metabolic profiling might be used to identify disease biomarkers. The aim of our study was to determine the usefulness of untargeted metabolomics analysis to detect differences in serum metabolites between newly diagnosed and untreated pediatric patients with Crohn's disease (CD) or ulcerative colitis (UC) in comparison with a control group (Ctr). Moreover, we investigated the potential of profiling metabolomics and inflammatory markers to improve the noninvasive diagnosis of CD and UC in children...
February 17, 2019: Inflammatory Bowel Diseases
https://read.qxmd.com/read/30772849/trial-summary-and-protocol-for-a-phase-ii-randomised-placebo-controlled-double-blinded-trial-of-interleukin-1-blockade-in-acute-severe-colitis-the-iaso-trial
#14
Martin Geoffrey Thomas, Carrie Bayliss, Simon Bond, Francis Dowling, James Galea, Vipul Jairath, Christopher Lamb, Christopher Probert, Elizabeth Timperley-Preece, Alastair Watson, Lynne Whitehead, John G Williams, Miles Parkes, Arthur Kaser, Tim Raine
INTRODUCTION: Acute severe ulcerative colitis (ASUC) is a severe manifestation of ulcerative colitis (UC) that warrants hospitalisation. Despite significant advances in therapeutic options for UC and in the medical management of steroid-refractory ASUC, the initial treatment paradigm has not changed since 1955 and is based on the use of intravenous corticosteroids. This treatment is successful in approximately 50% of patients but failure of this and subsequent medical therapy still occurs, with colectomy rates of up to 40% reported...
February 15, 2019: BMJ Open
https://read.qxmd.com/read/30771903/role-of-eosinophils-in-a-murine-model-of-inflammatory-bowel-disease
#15
Zi Wang, Soichiro Adachi, Lingling Kong, Daisuke Watanabe, Yusuke Nakanishi, Toshiaki Ohteki, Namiko Hoshi, Yuzo Kodama
Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD), which is triggered spontaneously by unknown mechanisms and manifests as chronic and relapsing inflammatory conditions in the colon. Eosinophil infiltration is often observed in the colonic tissue of ulcerative colitis patients. However, the role of eosinophils in the disease has not been well defined. The aim of this study is to investigate the role of eosinophils in colonic inflammation using the murine model of spontaneous colitis. CC chemokine receptor type 3 (CCR3) and interleukin (IL)-10 double knockout mice (CCR3-/-;IL-10-/-) were utilized to evaluate the function of eosinophils in colitis...
February 13, 2019: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/30771797/colocutaneous-fistula-through-ulcerative-colitis-and-cancer-to-the-pyoderma-gangrenosum-a-never-ending-story-for-a-single-patient-case-report
#16
Chiara Eberspacher, D Mascagni, L Fralleone, A Maturo, F M Di Matteo, F De Cristofaro, D Merletti, A Santoro, P Mascagni, S Pontone, D Pironi
BACKGROUND: Inflammatory bowel diseases may be associated with many extraintestinal complications, that in some cases can represent the first onset of these disorders. In particular during the course of the disease, Ulcerative Colitis develops extraintestinal manifestations very frequently. One of the rarest is pyoderma gangrenosum, a noninfectious neuthrophilic dermatosis, that can involve most commonly legs but also other parts of the skin or mucosas. It can be idiopathic or associated with gammopathies, vasculitis, chronic arthritis or, like in our case, with inflammatory bowel disease and malignancies...
January 2019: Il Giornale di Chirurgia
https://read.qxmd.com/read/30771793/thrombotic-complications-in-inflammatory-bowel-diseases
#17
REVIEW
R Fornaro, G Caristo, E Stratta, M Caratto, E Caratto, D Giovinazzo, L Di Maira, M Casaccia, M Frascio
Inflammatory bowel disease (IBD), Crohn's Disease (CD) and Ulcerative Colitis (UC) are associated with an increased risk of arterial and venous thromboembolism. A 2 to 3 time fold increased risk of developing thromboembolic complications was reported for IBD patients compared to general population. A systematic literature search was conducted using PubMed, Medline, Scopus, Cochrane database. The key words were: "Inflammatory Bowell Disease", "Crohn's Disease and Thrombosis", "Ulcerative Colitis and Thrombosis", "Thrombosis" and "Inflammatory Bowel Diseases and Thrombosis"...
January 2019: Il Giornale di Chirurgia
https://read.qxmd.com/read/30771347/itraq-based-pharmacoproteomics-reveals-potential-targets-of-berberine-a-promising-therapy-for-ulcerative-colitis
#18
Yan-Hong Li, Wei Sun, Bao-Jin Zhou, Adam Rosenstein, Jie Zhao, Jian Wang, Zhao-Xiang Bian
Previous studies by us and others have indicated that berberine is a promising therapy for ulcerative colitis (UC). However, the mechanisms of UC and the therapeutic targets of berberine are poorly understood. iTRAQ-based proteomics was utilized to characterize the proteins and pathways associated with the development of colitis and its improvement after berberine treatment. By using a dextran sodium sulfate (DSS) colitis as the UC model, we demonstrated that berberine significantly attenuated clinical symptoms and colon shorting of the colitis mice...
February 13, 2019: European Journal of Pharmacology
https://read.qxmd.com/read/30768495/short-term-results-after-totally-robotic-restorative-total-proctocolectomy-with-ileal-pouch-anal-anastomosis-for-ulcerative-colitis
#19
Ismail Hamzaoglu, Bilgi Baca, Eren Esen, Erman Aytac, Volkan Ozben, Afag Aghayeva, Ismail A Bilgin, Tayfun Karahasanoglu
In this study, we aimed to present our initial experience on totally robotic total restorative proctocolectomy in ulcerative colitis (UC) patients. Patients undergoing a totally robotic restorative total proctocolectomy with ileal J-pouch anal anastomosis for UC between January 2015 and November 2017 were included. The da Vinci Xi was used for the operations. Patient demographics, perioperative and short-term operative outcomes were evaluated. Ten patients were included. The median operative time was 380 minutes(range, 300 to 480 min)...
February 12, 2019: Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
https://read.qxmd.com/read/30768123/real-world-effectiveness-and-safety-of-vedolizumab-for-the-treatment-of-inflammatory-bowel-disease-the-scottish-vedolizumab-cohort
#20
N Plevris, C S Chuah, R M Allen, I D Arnott, P N Brennan, S Chaudhary, A M D Churchhouse, S Din, E Donoghue, D R Gaya, M Groome, H M Jafferbhoy, P W Jenkinson, W L Lam, M Lyons, J C Macdonald, M MacMaster, C Mowat, G D Naismith, L F Potts, E Saffouri, J P Seenan, A Sengupta, P Shasi, D I Sutherland, J A Todd, J Veryan, A J M Watson, D A Watts, G R Jones, C W Lees
INTRODUCTION: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. AIMS: To establish the real-world efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease. METHODS: Retrospective study involving six NHS health boards in Scotland between June 2015 and November 2017. Inclusion criteria included a diagnosis ulcerative colitis or Crohn's disease with objective evidence of active inflammation at baseline (HBI≥5 / Partial Mayo ≥2 plus CRP >5 g/L or faecal calprotectin ≥250 µg/g or inflammation on endoscopy / MRI) and at least one clinical follow up by 12 months...
February 14, 2019: Journal of Crohn's & Colitis
keyword
keyword
163019
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"